Washington, DC 20006-5349
HELPLINE
Kanwal Raghav, MD, discusses the results of a Phase 2 trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. Dr.…
Arkadiusz Dudek, MD, PhD, discusses the Phase 2 Nivolumab (Opdivo) + Ramucirumab clinical trial for previously-treated mesothelioma patients. The study is available at Moffitt Cancer…
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.…
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and…
Bristol Myers Squibb announced today that CheckMate -743, a pivotal phase 3 trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma, met its primary endpoint of overall…
A white paper documenting presentations and discussions from the Mesothelioma Patient Registry workshop, which was convened by the Mesothelioma Applied Research Foundation in March of…
In late August, the Mesothelioma Applied Research Foundation hosted an interview as part of its Meet the Mesothelioma Experts (MTME) series to discuss a new…
The New York Proton Center, the first proton therapy facility to open in the state of New York, began treating patients at its state-of-the-art East…
On Wednesday, August 28, 2019 at 8:00 PM EDT, the Meso Foundation’s Meet the Mesothelioma Experts live broadcast will feature Drs. Dan Sterman of NYU and Steve Albelda…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
